Many people overlook the importance of their right to vote. Voting is not something you should take for granted. Exercising your right to vote is an empowering event. This video explains why voting for ‘retention’ matters in Florida. Watch and see if you know why it matters.
#PROGRESSIVE settled with Fisher Family after Brother of deceased Sister uses Social Media to “out” claim handling and strategy of insurer.
USAToday reports a new vaginal ring study has commenced in Africa. The study will evaluate the effectiveness of an HIV preventing vaginal ring that releases DAPIVIRINE. To evaluate the ring certain women will be provided with a working ring, while others will be provided with one that does not contain DAPIVIRINE. Will this lead risky behavior and inconclusive results in women using the later? How will they ever know ? Could their ultimate infection have been avoided altogether by not participating?
DEVELOPING: GlaxoSmithKline Plc has agreed to plead guilty to criminal charges and pay $3 billion to settle the largest case of healthcare fraud in U.S. history, according to court filings and prosecutors.
The settlement includes $1 billion in criminal fines and $2 billion in civil fines in connection with the sale of the drug company’s Paxil, Wellbutrin and Avandia products.
Marissa Mayer’s appointment caps a tumultuous year at Yahoo. In May, Scott Thompson resigned as CEO after less than 6 months on the job as a controversy flared up over his academic credentials.
Thompson replaced the controversial and occasionally foul-mouthed Carol Bartz, fired in September after failing to revitalize Yahoo.
“She’s going to bring in a different perspective. It’s pretty clear Yahoo needs a new direction and really a new vision,” said Paul Buchheit, a Google engineer who helped create Gmail and now a partner at startup-incubator Y-Combinator.
“NEW DIET DRUG HELPS PATIENTS LOSE ABOUT 10% OF WEIGHT”
USAToday reports on the FDA’s recent approval of QYSMIA to combat obesity. The video above highlights the claimed benefits of the newest “weight-loss” pill that will soon be available to millions combating obesity. It was previously known as QNEXA and did not gain FDA approval under that name when originally considered. At the time, experts were concerned over added risks associated with heart rates. QYSMIA is intended for individuals that are obese, or 30 pounds over their target weight.
Health experts are already cautioning that the pills will not be a ‘magic pill’ that produces results. Rather, as W. Timothy Garvy, Chair of the Department of Nutrition Sciences at the University of Alabama-Birmingham, is quoted as stating, in USAToday:”This is not a magic pill. Patients can’t take it and think that’s all they have to do. It needs to be used with a lifestyle modification program”.
Public Citizen’s Sidney Wolfe has already been outspoken about the newly approved pill and is quoted as stating that it was “reckless” of the FDA to approve it because research has demonstrated it increases heart rate and at least 4 patients taking the pill had non-fatal heart attacks during the research phase.
USAToday reports that post-market surveillance on cardiovascular outcomes is planned but that results will not breadh for 4-5 years. QSYMIA is expected on shelves by the end of 2012.
PRADAXA Benefit Outweighs Bleeding Risk, FDA Says.
Is it True? Lawsuits may help answer questions over the drug that has now, as of May 2012, been linked to over 542 deaths underscoring the fact there is no antidote or quick reversal agent for the blood thinner.
Glaxo Smith Kline, or #GSK, recently agreed to pay $3 Billion Dollars in a record setting investigation by the Department of Justice (DOJ). The settlement centered around a number of questionable, and allegedly illegal business practices, in the promotion of a number of pharmaceutical products. This was an Exhibit in the DOJ investigation.
Cruises, Pheasant Hunting Trips, and Political Donations: The 5 Skeeziest GlaxoSmithKline Perks Revealed
PROPECIA and MERCK have been linked to alleged claims of sexual dysfunction in users. Lawsuits have been filed and MERCK continues to deny a scientific correlation between the claimed injuries and use of their product.
We are actively investigating cases involving use of PROPECIA and sexual dysfunction in young men who used the product for male pattern baldness. Contact requests may be sent thru a contact form from here.
In late June 2012, the U.S. Food & Drug Administration (“FDA”) held hearings over the course of 2 days to consider growing concerns and evidence relating to Metal on Metal (MoM) hip implants, resurfacing devices and other issues.
While most Americans celebrated mid-week July 4th, #STRYKER, a major manufacturer of hip implants announced that it was #recalling a failing component in its line of modular hip implants. By July 6th, PR releases from the company entitled “Stryker Initiates Voluntary Product Recall of Modular-Neck Stems, Action Specific to Rejuvenate and ABG II Modular-Neck Stems” announed that post-market surveillance had revealed potential risks of fretting and corrosion at the modular neck junction. This means that part of the joint, a stem like area that joined other components was failing and leading to serious complications and potential health risks for patients.
The image above is from Recall Attorneys / Recall Lawyers on Facebook. All of the surrounding PR and little news that has been publicized over this #recall highlights the fact that noone is putting a number on how many failed modular neck stems were manufactured, sold or implanted. Wonder if that is a deliberate failure on the part of #Stryker, or is it indicative of the fact that noone really knows. Until the dust settles on this #recall noone will know. Lawsuits related to the failure are imminent as patient advocates circle the wagons to seek answers and redress.
Additional information on existing Joint Recalls and related the ongoing investigation of the failure rate surrounding the previously recalled DePuy ASR, and now the Stryker Rejuvenate and ABG II Modular Neck Stems is available by contacting the sponsor of this site here.